List of Tables
Summary Table: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 1: Various Approaches to Anti-aging Therapeutics
Table 2: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
Table 3: Drugs and Biologics Related to Aging Under Various Phases of Clinical Trials, as of January 2019
Table 4: Global Population Aged 60 Years and Older, by Region, 2015, 2030 and 2050
Table 5: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
Table 6: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
Table 7: Household Disposable Income Across Selected Countries, 2012-2018
Table 8: Lifetime UV Exposure in the United States
Table 9: Start-up Companies in Anti-Aging Solutions
Table 10: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 11: Types of Senolytics Drugs
Table 12: Global Market for Senolytic Drug Therapy, by Region, Through 2023
Table 13: Population Aged 65 Years and Older, 2012-2017
Table 14: Global Market for Gene Therapy, by Region, Through 2023
Table 15: Leading Institutional Developers of Genomics Tools, 2017
Table 16: Global Market for Immunotherapy, by Region, Through 2023
Table 17: Global Market for Other Therapies, by Region, Through 2023
Table 18: Global Market for Longevity and Anti-senescence in Drug Discovery and Development, by Region, Through 2023
Table 19: Global Market for Longevity and Anti-senescence in Senescence Inhibition, by Region, Through 2023
Table 20: Global Market for Longevity and Anti-senescence in Cardiovascular Diseases, by Region, Through 2023
Table 21: Number of People with Dementia Worldwide, by Income Level, 2015-2050
Table 22: Investments in Alzheimer’s Disease Treatment
Table 23: Global Market for Longevity and Anti-senescence in Neural Degenerative Diseases, by Region, Through 2023
Table 24: Global Market for Longevity and Anti-senescence in Ophthalmology Disorders, by Region, Through 2023
Table 25: Global Number of Adults with Diabetes, 2015 and 2040
Table 26: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
Table 27: Percentage Increment of Diabetes Across Regions, 2015-2040
Table 28: Global Market for Longevity and Anti-senescence in Cancer, by Region, Through 2023
Table 29: Global Cancer Prevalence, by Type, 2016
Table 30: Cancer Prevalence Across Regions, by Type, 2015-2016
Table 31: North American Number and Distribution of Persons Aged 60 Years or Older, 2017 and 2050
Table 32: Demographic Indicators Related to Population Aging in North America, by Country, 2017 and 2050
Table 33: North American Market for Longevity and Anti-senescence, by Country, Through 2023
Table 34: North American Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 35: North American Market for Longevity and Anti-senescence, by Application, Through 2023
Table 36: United States’ Market for Longevity and Anti-senescence, by Application, Through 2023
Table 37: United States’ Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 38: Canadian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 39: Canadian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 40: European Market for Longevity and Anti-senescence, by Country, Through 2023
Table 41: European Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 42: European Market for Longevity and Anti-senescence, by Application, Through 2023
Table 43: U.K. Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 44: UK Market for Longevity and Anti-senescence, by Application, Through 2023
Table 45: French Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 46: French Market for Longevity and Anti-senescence, by Application, Through 2023
Table 47: German Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 48: German Market for Longevity and Anti-senescence, by Application, Through 2023
Table 49: Spanish Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 50: Spanish Market for Longevity and Anti-senescence, by Application, Through 2023
Table 51: Rest of the European Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 52: Rest of the European Market for Longevity and Anti-senescence, by Application, Through 2023
Table 53: Asia-Pacific Market for Longevity and Anti-senescence, by Country, Through 2023
Table 54: Asia-Pacific Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 55: Asia-Pacific Market for Longevity and Anti-senescence, by Application, Through 2023
Table 56: Chinese Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 57: Chinese Market for Longevity and Anti-senescence, by Application, Through 2023
Table 58: Total Rural Income in India, 2015 and 2021
Table 59: Indian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 60: Indian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 61: Share of Population Aged 65 Years and Older in Japan, 2015 and 2050
Table 62: Japanese Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 63: Japanese Market for Longevity and Anti-senescence, by Application, Through 2023
Table 64: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
Table 65: Australian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 66: Australian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 67: Rest of APAC Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 68: Rest of APAC Market for Longevity and Anti-senescence, by Application, Through 2023
Table 69: RoW Market for Longevity and Anti-senescence, by Region, Through 2023
Table 70: RoW Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 71: RoW Market for Longevity and Anti-senescence, by Application, Through 2023
Table 72: Latin American Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 73: Latin American Market for Longevity and Anti-senescence, by Application, Through 2023
Table 74: Disposable Income in UAE, 2010 and 2017
Table 75: Middle Eastern and African Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 76: Middle Eastern and African Market for Longevity and Anti-senescence, by Application, Through 2023
Table 77: Global Suppliers to Longevity and Anti-senescence Market
Table 78: Some of the Notable Longevity and Anti-senescence Companies
Table 79: Investment Analysis: Longevity and Anti-senescence Therapy Market
Table 80: Product Portfolio: Acorda Therapeutics
Table 81: Product Portfolio: AgeX Therapeutics
Table 82: Recent Developments: AgeX Therapeutics, 2016-2018
Table 83: Product Portfolio: Antoxerene
Table 84: Recent Developments: Antoxerene, 2016-2018
Table 85: Recent Developments: Calico Life Sciences, 2016-2018
Table 86: Product Portfolio: Celgene
Table 87: Product Portfolio: Cleara Biotech
Table 88: Recent Developments: Cleara Biotech, 2016-2018
Table 89: Product Portfolio: CohBar
Table 90: Recent Developments: CohBar, 2016-2018
Table 91: Product Portfolio: Human Longevity Inc.
Table 92: Recent Developments: Human Longevity Inc., 2016-2018
Table 93: Product Portfolio: Insilico Medicine
Table 94: Recent Developments: Insilico Medicine, 2016-2018
Table 95: Product Portfolio: Oisin Biotechnology
Table 96: Product Portfolio: PowerVision Inc.
Table 97: Recent Developments: PowerVision Inc., 2016-2018
Table 98: Product Portfolio: Prana Biotechnology Ltd.
Table 99: Recent Developments: Prana Biotechnology Ltd., 2016-2018
Table 100: Product Portfolio: Proteostasis Therapeutics Inc.
Table 101: Product Portfolio: Recursion Pharmaceuticals
Table 102: Recent Developments: Recursion Pharmaceuticals, 2016-2018
Table 103: Product Portfolio: resTORbio
Table 104: Product Portfolio (Pipeline): Senex Biotechnology
Table 105: Product Portfolio: Senolytic Therapeutics
Table 106: Product Portfolio: Spotlight Bioscience
Table 107: Product Portfolio: T.A. Sciences
Table 108: Recent Developments: T.A. Sciences, 2016-2018
Table 109: Product Portfolio: Unity Biotechnology
Table 110: Recent Developments: Unity Biotechnology, 2017-2019
List of Figures
Summary Figure: Global Market for Longevity and Anti-senescence, by Therapy, 2017-2023
Figure 1: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
Figure 2: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
Figure 3: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
Figure 4: Household Disposable Income Across Selected Countries, 2012-2018
Figure 5: Population Aged 65 Years and Older, 2012-2017
Figure 6: Number of People with Dementia Worldwide, by Income Level, 2015-2050
Figure 7: Global Number of Adults with Diabetes, 2015 and 2040
Figure 8: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
Figure 9: Percentage Distribution of Increasing Diabetes Cases, by Region, 2015-2040
Figure 10: Global Cancer Prevalence, by Type, 2016
Figure 11: Cancer Prevalence Across Regions, by Type, 2015-2016
Figure 12: Canadian Population Shares Distribution, by Province or Territory, 2018
Figure 13: Index of Mean and Median Equivalized Household Disposable Income in the U.K., 2015-2017
Figure 14: Geriatric Population in France, 2012 and 2017
Figure 15: Total Rural Income in India, 2015 and 2021
Figure 16: Share of Japanese Population Aged 65 Years and Older, 2015 and 2050
Figure 17: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
Figure 18: Disposable Income in UAE, 2010 and 2017
Figure 19: Industry Structure and Process Flow: Longevity and Anti-senescence Industry
